Evidence map›Paper›PMID 30488142›Full record

ArticleInflammation2019

Insulin Antagonizes LPS-Induced Inflammatory Responses by Activating SR-A1/ERK Axis in Macrophages.

Liu Zhu, Lei Fan, Yaqin Zhu, Yan Wang, Hui Bai, Qing Yang, Jingjing Ben, Hanwen Zhang, Xiaoyu Li, Xudong Zhu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Liu ZhuKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Lei FanKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Yaqin ZhuKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Yan WangKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Hui BaiKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Qing YangKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Jingjing BenKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Hanwen ZhangKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Xiaoyu LiKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China.
Xudong ZhuKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China. zhuxudong@njmu.edu.cn.
Qi ChenKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, No. 101, Longmian Road, Nanjing, 211166, Jiangsu, People's Republic of China. qichen@njmu.edu.cn.
Nanjing Medical University · CN

Funding

National Natural Science Foundation of China 81670263National Natural Science Foundation of China 81670418National Natural Science Foundation of China 81770417National Natural Science Foundation of China 81830011National Natural Science Foundation of China 81870371National Natural Science Foundation of China 91739304Natural Science Research of Jiangsu Higher Education Institutions of China 15KJA310001Natural Science Research of Jiangsu Higher Education Institutions of China 18KJA310003
6 · The paper itself

Abstract

Insulin is a key regulator of metabolism and inflammation in the body. However, the mechanism of the anti-inflammatory effect of insulin is not fully understood. In the present study, we investigated the role of the class A1 scavenger receptor (SR-A1), a prototypic member of the pattern recognition receptor family, in the insulin-mediated suppression of inflammatory responses in macrophages. Our murine in vivo studies show that insulin can attenuate lipopolysaccharide (LPS)-induced endotoxemia in a SR-A1-dependent manner, and this was consistent with our in vitro results which demonstrate that the SR-A1 is necessary for insulin to antagonize the LPS-induced inflammatory responses in macrophages. The effect of SR-A1 on the anti-inflammatory action of insulin might be associated with the activation of the extracellular signal-regulated kinases (ERK) signaling pathway in macrophages. Insulin could inhibit macrophage polarization to a pro-inflammatory phenotype via the SR-A1/ERK cascade. Collectively, our results suggest that SR-A1 may be a pivotal element for the anti-inflammation effect of insulin in macrophages.

Indexed as

AnimalsAnti-Inflammatory AgentsExtracellular Signal-Regulated MAP KinasesInflammationInsulinLipopolysaccharidesMacrophagesMiceScavenger Receptors, Class AAnti-Inflammatory AgentsExtracellular Signal-Regulated MAP KinasesInsulinLipopolysaccharidesMsr1 protein, mouseScavenger Receptors, Class Aanti-inflammationERK pathwayinsulinlipopolysaccharidescavenger receptor

Identifiers

PMID30488142
OpenAlexW2902744606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.